Angelo Claudio Molinari

List of Publications by Year
in descending order

96 papers	2,968 citations	172457 29 h-index	182427 51 g-index
102 all docs	102 docs citations	102 times ranked	2940 citing authors

#	Article	IF	Citations
1	F9 missense mutations impairing factor IX activation are associated with pleiotropic plasma phenotypes. Journal of Thrombosis and Haemostasis, 2022, 20, 69-81.	3.8	9
2	Current Choices and Management of Treatment in Persons with Severe Hemophilia A without Inhibitors: A Mini-Delphi Consensus. Journal of Clinical Medicine, 2022, 11, 801.	2.4	3
3	Safety and effectiveness of recombinant factor XIIIâ€A2 in congenital factor XIII deficiency: Realâ€world evidence. Research and Practice in Thrombosis and Haemostasis, 2022, 6, e12628.	2.3	3
4	Intracranial Haemorrhage in Haemophilia Patients Is Still an Open Issue: The Final Results of the Italian EMO.REC Registry. Journal of Clinical Medicine, 2022, 11, 1969.	2.4	6
5	Diagnosis and treatment of chronic synovitis in patients with haemophilia: consensus statements from the Italian Association of Haemophilia Centres. British Journal of Haematology, 2022, 196, 871-883.	2.5	7
6	Systemic Catheter-Related Venous Thromboembolism in Children: Data From the Italian Registry of Pediatric Thrombosis. Frontiers in Pediatrics, 2022, 10, 843643.	1.9	7
7	Use of the von Willebrand factor concentrate with low factor <scp>VIII</scp> content to manage patients with inherited von Willebrand disease requiring surgical or secondary longâ€term prophylaxis: an expert opinion paper from an Italian panel. European Journal of Haematology, 2022, , .	2.2	1
8	Variability of treatment modalities and intensity in patients with severe haemophilia A on prophylaxis: Results from the Italian national registry. European Journal of Haematology, 2021, 107, 408-415.	2.2	0
9	Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial. Lancet Haematology,the, 2020, 7, e18-e27.	4.6	173
10	Cost-Effectiveness and Budget Impact of Emicizumab Prophylaxis in Haemophilia A Patients with Inhibitors. Thrombosis and Haemostasis, 2020, 120, 216-228.	3.4	48
11	Bivalirudin anticoagulation to overcome heparin resistance in a neonate with cerebral sinovenus thrombosis. Blood Coagulation and Fibrinolysis, 2020, 31, 97-100.	1.0	5
12	Bodyweight-adjusted rivaroxaban for children with venous thromboembolism (EINSTEIN-Jr): results from three multicentre, single-arm, phase 2 studies. Lancet Haematology,the, 2019, 6, e500-e509.	4.6	51
13	Consensus statements on vaccination in patients with haemophiliaâ€"Results from the Italian haemophilia and vaccinations (HEVA) project. Haemophilia, 2019, 25, 656-667.	2.1	16
14	ABCC6 mutations and early onset stroke: Two cases of a typical Pseudoxanthoma Elasticum. European Journal of Paediatric Neurology, 2018, 22, 725-728.	1.6	15
15	Rivaroxaban versus standard anticoagulation for acute venous thromboembolism in childhood. Design of the EINSTEIN-Jr phase III study. Thrombosis Journal, 2018, 16, 34.	2.1	28
16	Pain assessment and management in haemophilia: A survey among Italian patients and specialist physicians. Haemophilia, 2018, 24, 766-773.	2.1	26
17	Neonatal Systemic Thrombosis: An Updated Overview. Current Vascular Pharmacology, 2018, 16, 499-509.	1.7	11
18	Successful of Immune Tolerance Induction (R-ITI) with Simoctocog Alfa (rhFVIII) in Hemophilia a Patients and High-Titer Inhibitors. Blood, 2018, 132, 5036-5036.	1.4	0

#	Article	IF	Citations
19	Costâ€effectiveness analysis of late prophylaxis vs. onâ€demand treatment for severe haemophilia A in Italy. Haemophilia, 2017, 23, 422-429.	2.1	7
20	Intracranial haemorrhage in children and adolescents with severe haemophilia A or B â€“ the impact of prophylactic treatment. British Journal of Haematology, 2017, 179, 298-307.	2.5	56
21	Brachiocephalic vein for percutaneous ultrasound-guided central line positioning in children: A 20-month preliminary experience with 109 procedures. Pediatric Blood and Cancer, 2017, 64, 330-335.	1.5	15
22	Risk Factors for the Progression from Low to High Titres in 260 Children with Severe Haemophilia A and Newly Developed Inhibitors. Thrombosis and Haemostasis, 2017, 117, 2274-2282.	3.4	13
23	Hemophilia Care in the Pediatric Age. Journal of Clinical Medicine, 2017, 6, 54.	2.4	39
24	[Use of KovaltryÂ® in patients with Hemophilia A: clinical and economical aspects from the pivotal clinical trials]. Farmeconomia E Percorsi Terapeutici, 2017, 18, .	0.1	0
25	Liver Transplantation in Type III von Willebrand Disease. American Journal of Transplantation, 2016, 16, 1936-1937.	4.7	1
26	Clinical Data of Neonatal Systemic Thrombosis. Journal of Pediatrics, 2016, 171, 60-66.e1.	1.8	54
27	Risk Factors for the Development of High-Titer Inhibitors in 260 Children with Severe Hemophilia a Born Between 1990 and 2009: The Remain Study. Blood, 2016, 128, 3774-3774.	1.4	0
28	Health economic models in hemophilia A and utility assumptions from a clinician's perspective. Pediatric Blood and Cancer, 2015, 62, 1826-1831.	1.5	19
29	Benefits of prophylaxis versus on-demand treatment in adolescents and adults with severe haemophilia A: the POTTER study. Thrombosis and Haemostasis, 2015, 114, 35-45.	3.4	87
30	Central Venous access Devices in Pediatric Malignancies: A Position Paper of Italian Association of Pediatric Hematology and Oncology. Journal of Vascular Access, 2015, 16, 130-136.	0.9	38
31	Paediatric arterial ischaemic stroke and cerebral sinovenous thrombosis. Thrombosis and Haemostasis, 2015, 113, 1270-1277.	3.4	28
32	Recommendations for the use of long-term central venous catheter (CVC) in children with hemato-oncological disorders: management of CVC-related occlusion and CVC-related thrombosis. On behalf of the coagulation defects working group and the supportive therapy working group of the Italian Association of Pediatric Hematology and Oncology (AIEOP). Annals of Hematology, 2015, 94, 1765-1776.	1.8	34
33	A Practical Approach to the Use of Low Molecular Weight Heparins in VTE Treatment and Prophylaxis in Children and Newborns. Pediatric Hematology and Oncology, 2015, 32, 1-10.	0.8	26
34	Acquired inhibitors of clotting factors: AICE recommendations for diagnosis and management. Blood Transfusion, 2015, 13, 498-513.	0.4	48
35	Prophylaxis therapy in paediatric patients with haemophilia: a survey of clinical management trends in Italy. Blood Transfusion, 2015, 13, 631-8.	0.4	3
36	Current Management of the Hemophilic Child: A Demanding Interlocutor. Quality of Life and Adequate Cost-Efficacy Analysis. Pediatric Hematology and Oncology, 2014, 31, 687-702.	0.8	26

#	Article	IF	Citations
37	Perceived challenges and attitudes to regimen and product selection from Italian haemophilia treaters: the 2013 <scp>AICE</scp> survey. Haemophilia, 2014, 20, e128-35.	2.1	15
38	Sirolimus as Maintenance Treatment in an Infant With Life-threatening Multiresistant Pure Red Cell Anemia/Autoimmune Hemolytic Anemia. Journal of Pediatric Hematology/Oncology, 2014, 36, e145-e148.	0.6	11
39	Successful urgent neurosugery management with rFVIIa mega doses in a child with haemophilia A and high titre inhibitor. Blood Coagulation and Fibrinolysis, 2014, 25, 518-521.	1.0	6
40	Similar bleeding phenotype in young children with haemophilia A or B: a cohort study. Haemophilia, 2014, 20, 747-755.	2.1	35
41	Therapeutic management and costs of severe haemophilia A patients with inhibitors in Italy. Haemophilia, 2014, 20, e243-50.	2.1	19
42	Principles of treatment and update of recommendations for the management of haemophilia and congenital bleeding disorders in Italy. Blood Transfusion, 2014, 12, 575-98.	0.4	52
43	Issues in pediatric haemophilia care. Italian Journal of Pediatrics, 2013, 39, 24.	2.6	25
44	Factor VIII Products and Inhibitor Development in Severe Hemophilia A. New England Journal of Medicine, 2013, 368, 231-239.	27.0	383
45	Emerging Issues on Comprehensive Hemophilia Care: Preventing, Identifying, and Monitoring Age-Related Comorbidities. Seminars in Thrombosis and Hemostasis, 2013, 39, 794-802.	2.7	29
46	Development and definition of a simplified scanning procedure and scoring method for Haemophilia Early Arthropathy Detection with Ultrasound (HEAD-US). Thrombosis and Haemostasis, 2013, 109, 1170-1179.	3.4	188
47	Prevention of venous thromboembolism in patients with cancer: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET)1. Thrombosis Research, 2012, 129, e171-e176.	1.7	46
48	A Practical Approach to Diagnosis and Treatment of Symptomatic Thromboembolic Events in Children with Acute Lymphoblastic Leukem. , 2012, , 307-323.		0
49	Venous thrombosis in children. Blood Coagulation and Fibrinolysis, 2011, 22, 351-361.	1.0	15
50	Shifting from open surgical cut down to ultrasound-guided percutaneous central venous catheterization in children: learning curve and related complications. Pediatric Surgery International, 2010, 26, 819-824.	1.4	32
51	Prospective study of hemostatic alterations in children with acute lymphoblastic leukemia. American Journal of Hematology, 2010, 85, 325-330.	4.1	64
52	Management of Chronic Childhood Immune Thrombocytopenic Purpura: AIEOP Consensus Guidelines. Acta Haematologica, 2010, 123, 96-109.	1.4	56
53	Incidence of indwelling central venous catheter-related complications using the Sri Paran technique for device fixation in children with cancer. Pediatric Surgery International, 2009, 25, 591-594.	1.4	7
54	Forum on: the role of recombinant factor VIII in children with severe haemophilia A. Haemophilia, 2009, 15, 578-586.	2.1	20

#	Article	IF	Citations
55	Multiplex ligationâ€dependent probe amplification to detect a large deletion within the von Willebrand gene. Haemophilia, 2009, 15, 1346-1348.	2.1	12
56	Rituximabâ€based immunosuppression for autoimmune haemolytic anaemia in infants. British Journal of Haematology, 2009, 145, 96-100.	2.5	17
57	Management and investigation of neonatal thromboembolic events: Genetic and acquired risk factors. Thrombosis Research, 2009, 123, 805-809.	1.7	41
58	Management of bleeding and of invasive procedures in patients with platelet disorders and/or thrombocytopenia: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET). Thrombosis Research, 2009, 124, e13-e18.	1.7	64
59	MLPA assay in F8 gene mutation screening. Haemophilia, 2008, 14, 625-627.	2.1	18
60	Management of Acute Childhood Idiopathic Thrombocytopenic Purpura according to AIEOP Consensus Guidelines: Assessment of Italian Experience. Acta Haematologica, 2008, 119, 1-7.	1.4	30
61	The Italian AICE-Genetics hemophilia A database: results and correlation with clinical phenotype. Haematologica, 2008, 93, 722-728.	3.5	95
62	von Willebrand Factor, von Willebrand Factor-Cleaving Protease, and Shear Stress. Cardiovascular and Hematological Agents in Medicinal Chemistry, 2007, 5, 305-310.	1.0	8
63	A Practical Approach to Diagnosis and Treatment of Symptomatic Thromboembolic Events in Children with Acute Lymphoblastic Leukemia: Recommendations of the “Coagulation Defects” AIEOP Working Group. Recent Patents on Cardiovascular Drug Discovery, 2007, 2, 53-62.	1.5	13
64	Incidence of catheter-related infections within 30 days from insertion of Hickmanâ€“Broviac catheters. Pediatric Blood and Cancer, 2007, 48, 35-38.	1.5	16
65	ADAMTS-13 activity in von Willebrand disease. Thrombosis Research, 2006, 117, 685-688.	1.7	6
66	Metabolic and Genetic Risk Factors for Migraine in Children. Cephalalgia, 2006, 26, 731-737.	3.9	58
67	Insight into molecular changes of the FIX protein in a series of Italian patients with haemophilia B. Haemophilia, 2006, 12, 263-270.	2.1	15
68	Cerebrovascular disease and varicella in children. Brain and Development, 2006, 28, 366-370.	1.1	42
69	von Willebrand factor multimer composition is modified following oral methionine load in women with thrombosis, but not in healthy women. Blood Coagulation and Fibrinolysis, 2005, 16, 267-273.	1.0	4
70	Cleavage of von Willebrand factor by ADAMTS-13 in vitro: effect of temperature and barium ions on the proteolysis kinetics. Blood Coagulation and Fibrinolysis, 2005, 16, 607-611.	1.0	6
71	Familial nonrandom inactivation linked to the X inactivation centre in heterozygotes manifesting haemophilia A. European Journal of Human Genetics, 2005, 13, 635-640.	2.8	36
72	Small FVIII gene rearrangements in 18 hemophilia A patients: Five novel mutations. American Journal of Hematology, 2005, 78, 117-122.	4.1	3

#	Article	IF	Citations
73	Correlation between â€œmalfunctioning eventsâ€•and catheter-related infections in pediatric cancer patients bearing tunneled indwelling central venous catheter: results of a prospective observational study. Supportive Care in Cancer, 2005, 13, 757-759.	2.2	6
74	Central venous catheter-related complications in children with oncological/hematological diseases: an observational study of 418 devices. Annals of Oncology, 2005, 16, 648-654.	1.2	187
75	Von Willebrand factor cleaving protease (ADAMTS-13) activity is stable in a set of plasma samples after prolonged storage at â˜80 Â°C. Thrombosis Research, 2005, 116, 443-445.	1.7	3
76	Caspofungin associated with liposomal amphotericin B or voriconazole for treatment of refractory fungal pneumonia in children with acute leukaemia or undergoing allogeneic bone marrow transplant. Clinical Microbiology and Infection, 2004, 10, 255-257.	6.0	29
77	Identification of mutations in exon 14 including five novelties in 13 Italian patients with haemophilia A. Haemophilia, 2004, 10, 744-746.	2.1	1
78	Urokinase for restoring patency of malfunctioning or blocked central venous catheters in children with hemato-oncological diseases. Supportive Care in Cancer, 2004, 12, 840-843.	2.2	15
79	A single institution observational study of early mechanical complications in central venous catheters (valved and open-ended) in children with cancer. Pediatric Surgery International, 2004, 20, 704-707.	1.4	8
80	Germ-line origin of intronÂ1 inversion in two haemophiliaÂA families. Haemophilia, 2003, 9, 717-720.	2.1	4
81	Conditions associated with infections of indwelling central venous catheters in cancer patients: a summary. British Journal of Haematology, 2003, 121, 233-239.	2.5	27
82	Analysis of 18 novel mutations in the factor VIII gene. British Journal of Haematology, 2003, 122, 810-817.	2.5	16
83	Prospective Study of Indwelling Central Venous Catheter-Related Complications in Children With Broviac or Clampless Valved Catheters. Journal of Pediatric Hematology/Oncology, 2002, 24, 657-661.	0.6	34
84	The role of heparin prophylaxis and Doppler ultrasound examination in preventing and diagnosing central venous catheter related complications. Supportive Care in Cancer, 2002, 10, 260-261.	2.2	1
85	Thromboembolic complications related to indwelling central venous catheters in children with oncological/haematological diseases: a retrospective study of 362 catheters. Supportive Care in Cancer, 2001, 9, 539-544.	2.2	43
86	MECHANICAL COMPLICATIONS RELATED TO INDWELLING CENTRAL VENOUS CATHETER IN PEDIATRIC HEMATOLOGY/ONCOLOGY PATIENTS. Pediatric Hematology and Oncology, 2001, 18, 317-324.	0.8	27
87	Recurrent antiphospholipid-related deep vein thrombosis as presenting manifestation of systemic lupus erythematosus. European Journal of Pediatrics, 2000, 159, 211-214.	2.7	8
88	Deep Venous Thrombosis Associated with Antiphospholipid Antibodies in an Adolescent after Exeresis of a Pilocytic Astrocytoma. Pediatric Neurosurgery, 1996, 25, 323-324.	0.7	1
89	ANTIPHOSPHOLIPID ANTIBODIES IN PAEDIATRIC SYSTEMIC LUPUS ERYTHEMATOSUS, JUVENILE CHRONIC ARTHRITIS AND OVERLAP SYNDROMES: SLE PATIENTS WITH BOTH LUPUS ANTICOAGULANT AND HIGH-TITRE ANTICARDIOLIPIN ANTIBODIES ARE AT RISK FOR CLINICAL MANIFESTATIONS RELATED TO THE ANTIPHOSPHOLIPID SYNDROME. Rheumatology, 1995, 34, 873-881.	1.9	58
90	Changing pattern of pathogens causing broviac catheter-related bacteraemias in children with cancer. Journal of Hospital Infection, 1995, 29, 129-133.	2.9	36

#	Article	IF	Citations
91	A PEDIATRIC CASE OF PURE RED CELL APLASIA: SUCCESSFUL TREATMENT WITH ANTI-LYMPHOCYTE GLOBULIN AND CORRELATION WITH IN VITRO T CELL-MEDIATED INHIBITION OF ERYTHROPOIESIS. British Journal of Haematology, 1991, 79, 129-130.	2.5	5
92	Evaluation of factor VIII pharmacokinetics in hemophilia-A subjects undergoing surgery and description of a nomogram for dosing calculations. American Journal of Hematology, 1989, 30, 140-149.	4.1	23
93	Timing of booster immunizations with hepatitis B vaccine. Transfusion, 1987, 27, 443-444.	1.6	0
94	Congenital Dyserythropoietic Anemia Type I: Report of a Pair of Siblings. Acta Haematologica, 1986, 75, 219-223.	1.4	6
95	Hepatitis B virus infection in patients with antibody to hepatitis B surface antigen. Transfusion, 1985, 25, 289-290.	1.6	1
96	Evidence for a 1980 HTLV-III Infection in a Currently Asymptomatic B Hemophiliac in Italy. JAMA - Journal of the American Medical Association, 1985, 254, 1449.	7.4	2